StockNews.com Initiates Coverage on OpGen (NASDAQ:OPGN)

StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN) in a report issued on Wednesday. The firm issued a sell rating on the medical research company’s stock.

OpGen Stock Performance

Shares of NASDAQ:OPGN opened at $1.75 on Wednesday. The stock’s fifty day simple moving average is $1.96 and its two-hundred day simple moving average is $3.17. OpGen has a 1-year low of $1.61 and a 1-year high of $11.20.

OpGen (NASDAQ:OPGN) last released its quarterly earnings results on Monday, August 19th. The medical research company reported ($1.18) earnings per share for the quarter. The company had revenue of $0.03 million for the quarter.

Institutional Trading of OpGen

A hedge fund recently bought a new stake in OpGen stock. Chase Investment Counsel Corp bought a new stake in shares of OpGen, Inc. (NASDAQ:OPGN) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned about 2.63% of OpGen at the end of the most recent reporting period. 2.68% of the stock is owned by institutional investors and hedge funds.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.